Status: Recruiting
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
This trial is designed to investigate the safety, response rates and survival outcomes of patients with inoperable lung cancer by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).
Participants needed: 90
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Second Affiliated Hospital of Guangzhou Medical UniversityUpdated: Jul 3, 2024Locations: 1
Eligibility criteria
Cytohistological confirmation is required for diagnosis of cancer. [+8]
Patients participated in clinical trials of equipment or drugs (signed informed... [+8]